Vistagen Therapeutics Inc — Cash Flow (NASDAQ:VTGN) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -12.07 M-45.26 M-49.72 M-25.81 M-42.1 M -60.3 M Cash from investing activities -275.4 K-200.4 K-740.3 K-61 K-13.15 M -251 K Cash from financing activities 114.1 M10.48 M-1.04 M128.4 M3.21 M 33.2 M Free cash flow -12.35 M-45.46 M-50.24 M-25.81 M-42.1 M -60.45 M

News

Vistagen Therapeutics reduces workforce by 20 percent to manage costs

VistaGen at TD Cowen Conference: Pherine Platform in Focus

Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%

Jefferies downgrades VistaGen stock rating to Hold on failed Phase III trial

VistaGen stock rating downgraded by William Blair after trial miss

Stifel downgrades VistaGen stock to Hold as anxiety drug fails in trial

Vistagen stock plummets after failed anxiety treatment trial

Vistagen’s anxiety treatment fails to meet primary endpoint in trial